



Doc Code:

PTO/SB/82 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	09/595,218
	Filing Date	June 16, 2000
	First Named Inventor	Elfi Biedermann
	Art Unit	1625
	Examiner Name	Zinna Northington Davis
	Attorney Docket Number	19710

I hereby revoke all previous powers of attorney given in the above-identified application:

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number:

00272

☒ Please change the correspondence address for the above-identified application to:☒ The address associated with
Customer Number:

23389

OR

<input type="checkbox"/> Firm or Individual Name					
Address					
City		State		ZIP	
Country					
Telephone		Email			

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71
Statement under 37CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**

Signature			
Name	Katrin Becker		
Date	July 6, 2006	Telephone	+49 89 4544-2062


NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ *Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code:



PTO/SB/96 (12-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Astellas Pharma GmbH

Application No./Patent No./Control No.: 09/595,218 Filed/Issue Date: June 16, 2000

Entitled: CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, ALKINE CARBOXAMIDES
USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS

Astellas Pharma GmbH

, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at _____, Frame _____, or a true copy of the original is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Katrin Becker

Signature

Katrin Becker

Printed or Typed Name

Director Legal Affairs

Title

July 6, 2006

Date

+49 89 4544-2062

Telephone number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


A S S I G N M E N T

WE, ELFI BIEDERMANN, residing in Vaterstetten, Germany; MAX HASMANN, residing in Neuried, Germany; ROLAND LÖSER, residing in Feldafing, Germany; BENNO RATTEL, residing in Munich, Germany; FRIEDEMANN REITER residing in Putzbrunn, Germany; BARBARA SCHEIN residing in Neufahrn, Germany; KLAUS SEIBEL residing in Grafelfing, Germany; KLAUS VOGT residing in Munich, Germany; KATJA WOSIKOWSKI residing in Poing, Germany; and ISABEL SCHMAINDA residing in Munich, Germany, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned and do hereby assign to Klinge Pharma GmbH, having a principle place of business at Berg-am-Laim-Strasse 129, D-81673 Munich, Germany, its successors, assigns and legal representatives (Assignee), the entire right, title and interest in and to all subject matter invented by us and disclosed in U.S. Application No. 09/595,218, which is a continuation of International Patent Application No. PCT/EP98/08267, filed 16 December 1998, entitled


**CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE,
ALKENE AND ALKINE CARBOXAMIDES USEFUL A
CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS**

and in and to all Patent and all Convention and Treaty rights of all kinds including the rights to claim priority therefrom, in the United States of America, for all such subject matter. We agree to sign all documents necessary to secure all said Patents and rights, and request issuance of all said Patents to the above assignee in accordance with this request.

25.10. , 2000


Elfi Biedermann

25.10. , 2000



Max Hasmann

BEST AVAILABLE COPY

ASSIGNMENT

Atty. Dkt. No. 69053

25.10., 2000


Roland Löser


25.10., 2000


Benno Rattel

25.10., 2000


Friedemann Reiter

25.10., 2000


Barbara Schein


25.10., 2000


Klaus Seibel

25.10., 2000


Klaus Vogt

25.10., 2000


Katja Wosikowski

25.10., 2000


Isabel Schemainda